Breast Cancer Research and Treatment

, Volume 22, Issue 1, pp 101–106 | Cite as

Interference of the IGF system as a strategy to inhibit breast cancer growth

  • Carlos L. Arteaga


Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.

Key words

anti-IGF-receptor antibodies autocrine growth regulation breast cancer cells growth inhibition IGF-I IGF-II IGF receptors paracrine growth regulation therapeutic modalities 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furlanetto RW, DiCarlo JN: Somatomedin-C receptors and growth effects in human breast cancer cells maintained in long-term tissue culture. Cancer Res 44:2122–2128, 1984PubMedGoogle Scholar
  2. 2.
    Myal Y, Shiu RPC, Bhaumick B, Bala M: Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 44:5486–5490, 1984PubMedGoogle Scholar
  3. 3.
    Huff KK, Kaufman D, Gabbay KH, Spencer M, Lippman ME, Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46:4613–4619, 1986PubMedGoogle Scholar
  4. 4.
    Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SAW, Ramasharma K, Marshall M, Li CH: Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701–1709, 1989PubMedGoogle Scholar
  5. 5.
    Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48–53, 1990PubMedGoogle Scholar
  6. 6.
    Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID: Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: Potential autocrine role of IGF-II. Mol Endocrinol 5:709–717, 1991PubMedGoogle Scholar
  7. 7.
    Dickson RB, McManaway ME, Lippman ME: Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232:1540–1543, 1986PubMedGoogle Scholar
  8. 8.
    Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP, Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17-ß-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84:837–841, 1987PubMedGoogle Scholar
  9. 9.
    Stewart AJ, Johnson MD, May FEB, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172–21178, 1990PubMedGoogle Scholar
  10. 10.
    Pekonen F, Partanen S, Makinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343–1347, 1988PubMedGoogle Scholar
  11. 11.
    Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509–517, 1989PubMedGoogle Scholar
  12. 12.
    Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48:6691–6696, 1988PubMedGoogle Scholar
  13. 13.
    Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME: Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978–4985, 1991PubMedGoogle Scholar
  14. 14.
    Kull FC, Jacobs S, Su Y-F, Svoboda ME, Van Wyk JJ, Cuatrecasas P: Monoclonal antibodies to receptor for insulin and somatomedin-C. J Biol Chem 258:6561–6566, 1983PubMedGoogle Scholar
  15. 15.
    Jacobs S, Cook S, Svoboda ME, Van Wyk JJ: Interaction of the monoclonal antibodies α-IR-1 and α-IR-3 with insulin and somatomedin-C receptors. Endocrinology 118:223–226, 1989Google Scholar
  16. 16.
    Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237–6241, 1989PubMedGoogle Scholar
  17. 17.
    Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–1423, 1989PubMedGoogle Scholar
  18. 18.
    Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E: The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 25:21544–21549, 1989Google Scholar
  19. 19.
    Milazzo G, Yip CC, Maddux BA, Vigneri R, Goldfine ID: High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. J Clin Invest 89:899–908, 1992PubMedGoogle Scholar
  20. 20.
    Colletti RB, Roberts JD, Devlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49:1882–1884, 1989PubMedGoogle Scholar
  21. 21.
    Pollak MN, Polychronakos C, Guyda H: Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889–892, 1989PubMedGoogle Scholar
  22. 22.
    Yee D, Favoni RE, Lupu R, Cullen KJ, Lebovic GS, Huff KK, Lee PDK, Lee YL, Powell DR, Dickson RB, Rosen N, Lippman ME: The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. Biochem Biophys Res Commun 158:38–44, 1989PubMedGoogle Scholar
  23. 23.
    De Leon DD, Wilson DM, Bakker B, Lamson G, Hintz RL, Rosenfeld RG: Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Mol Endocrinol 3:567–574, 1989PubMedGoogle Scholar
  24. 24.
    van der Burg B, Isbrucker L, van Selm-Miltenburg AJP, de Laat SW, van Zoelen EJJ: Role of estrogen-induced insulin-like growth factors in the proliferation of human breast cancer cells. Cancer Res 50:7770–7774, 1990PubMedGoogle Scholar
  25. 25.
    Figueroa JA, Jackson JG, McGuire WL, Powell DR, Yee D: Expression of insulin-like growth factor binding proteins (IGFBPs) in human breast cancer cell lines and primary tumors: Potential role as modulators of insulin-like growth factor action. Proc Amer Assoc Cancer Res 33:274a, 1992Google Scholar
  26. 26.
    Ennis BW, Valverius EM, Bates SE, et al: Anti-epidermal growth factor receptor antibodies inhibit the autocrine stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3:1830–1839, 1989PubMedGoogle Scholar
  27. 27.
    Sato JD, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511, 1983PubMedGoogle Scholar
  28. 28.
    Pastan I, Fitzgerald D: Recombinant toxins for cancer treatment. Science 254:1173–1177, 1991PubMedGoogle Scholar
  29. 29.
    Peyrat J-P, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48:6429–6433, 1988PubMedGoogle Scholar
  30. 30.
    Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic significance of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Carlos L. Arteaga
    • 1
  1. 1.Departments of Medicine and Cell BiologyVanderbilt UniversityNashvilleUSA

Personalised recommendations